Buzzing stock : Ajanta Pharma surges ahead with the launch of drug to treat migraine
DSIJ Intelligence / 31 Aug 2017
Ajanta Pharma has received USFDA’s nod for Eletriptan Hydrobromide Tablet, a pain-relieving drug used in the treatment of migraine.
Ajanta Pharma has received USFDA’s nod for Eletriptan Hydrobromide Tablet, a pain-relieving drug used in the treatment of migraine.
It has launched these tablets in the US markets with its fully-owned subsidiary, Ajanta Pharma, USA Inc.
The drug is a bioequivalent generic version of Replax Tablet. The company has launched this product in two strengths, namely, 40 mg and 20 mg respectively.
Further it has mentioned in its filing that till now the company has launched 14 products in the US market. Also, with 14 ANDAs (Abbreviated New Drug Applications) under review, two tentative approvals and 19 final ANDA approvals, it has a healthy pipeline of 35 ANDAs.
In today’s trade, the stock has opened at Rs 1,197 and touched a high and low of Rs 1,225.05 and Rs 1,192.95, respectively. At 12:12 pm hours the stock was quoting at Rs 1,198 per share.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.